lamotrigine IV / CURx Pharma, Ligand - LARVOL DELTA

Development of in vitro-in vivo correlation for establishing patient-centric quality standards of dissolution for lamotrigine extended-release tablets. (PubMed, Eur J Pharm Biopharm) - "This PBPK model was developed and verified using plasma lamotrigine profiles following administration of lamotrigine intravenous (IV) solution and oral immediate-release (IR) tablets. Using these dissolution conditions, a PCQS of ≤10 % release at 2 h, ≤45 % at 6 h, and ≥80 % at 18 h was derived. In conclusion, this study demonstrates that a PCQS for lamotrigine ER tablets dissolution can be established using verified PBPK and validated IVIVC model and offers a reliable approach for assessment of product performance."

Journal • Preclinical

Pharmacological Treatment of Trigeminal Neuralgia (PubMed, No Shinkei Geka) - "The alternatives to carbamazepine include gabapentin, pregabalin, and microgabalin. Although used off-label in Japan, baclofen, lamotrigine, intravenous lidocaine, and botulinum toxin type A are also effective...Carbamazepine and lamotrigine are particularly likely to cause severe drug eruptions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. Low-dose titration is important to avoid the development of rashes and adverse effects."

Journal • Hepatology • Liver Failure • Neuralgia • Pain • Steven-Johnson Syndrome

Reverse translational analysis of clinically reported, lamotrigine-induced cardiovascular adverse events using the halothane-anesthetized dogs. (PubMed, Heart Vessels) - "Lamotrigine was intravenously administered in doses of 0.1, 1 and 10 mg/kg/10 min under the monitoring of cardiovascular variables, possibly providing subtherapeutic to supratherapeutic plasma concentrations...This finding may partly explain the onset mechanism of lamotrigine-associated cardiac adverse events in the clinical cases. In addition, elevation of J wave was induced in half of the animals, suggesting that lamotrigine may have some potential to unmask Brugada electrocardiographic genotype in susceptible patients."

Adverse events • Clinical • Journal • Anesthesia • Bipolar Disorder • Cardiovascular • CNS Disorders • Epilepsy • Hypotension • Mood Disorders • Psychiatry

[VIRTUAL] Sphenopalatine Ganglion Block for the Treatment of SUNCT Syndrome in a Geriatric Patient (AHS 2020) - "Lamotrigine and intravenous lidocaine have been shown to help modulate the pain in SUNCT syndrome, though many patients remain difficult to manage and refractory to these medications...She was trialed on but failed oxygen therapy, topiramate, nortriptyline, oxcarbazepine, gabapentin, supra-orbital and occipital nerve blocks, and intravenous magnesium... Patients with SUNCT can often be refractory to standard headache medications, and side effects from medications, drug interactions, and tolerability can be a limiting factor in the choice of oral treatments for elderly patients. SPG block is a safe, office-based, and non-invasive procedure that can be considered for treatment of pain in elderly patients with SUNCT."

Clinical • CNS Disorders • Pain • MRI